Craig Hallum Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)

Equities researchers at Craig Hallum initiated coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research report issued on Friday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $12.00 price target on the stock. Craig Hallum’s price target suggests a potential upside of 238.03% from the company’s previous close.

Several other research analysts have also recently commented on the stock. Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price on the stock. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th.

Eupraxia Pharmaceuticals Trading Up 5.7 %

Shares of EPRX opened at $3.55 on Friday. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $5.22. The firm’s 50 day moving average is $3.13 and its 200-day moving average is $2.90. The stock has a market capitalization of $126.56 million and a PE ratio of -4.93.

Institutional Trading of Eupraxia Pharmaceuticals

Large investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter worth approximately $31,000. Raymond James Financial Inc. acquired a new stake in Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, Bank of Montreal Can boosted its position in Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock valued at $178,000 after buying an additional 7,500 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.